Oncotype DX recurrence score is used to guide adjuvant chemotherapy decision-making in which specific subgroup of breast cancer patients?

• A ER-negative, HER2-positive, node-negative patients
• B Triple-negative breast cancer with high-grade histology
• C BRCA1-mutated patients regardless of receptor status
• D ER-positive, HER2-negative, node-negative or limited node-positive patients ✓

Explanation

Oncotype DX is a 21-gene recurrence score assay validated for ER-positive, HER2-negative, node-negative (and selected node-positive) early breast cancer to predict the benefit of adjuvant chemotherapy. The TAILORx trial demonstrated that patients with intermediate scores (11-25) do not benefit from adding chemotherapy to endocrine therapy. It is not applicable to ER-negative or HER2-positive tumors where chemotherapy is typically recommended regardless.

Reference: Bailey & Love's Short Practice of Surgery, 27th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.